Loading company…
Shanghai Yingli researches and develops small molecule drugs for cancer, autoimmune diseases and metabolic disorders.
Established in 2011 and based in Shanghai, China, Shanghai Yingli Pharmaceutical researches and develops small molecule drugs for cancer, autoimmune diseases and metabolic disorders. Its products include YY-20394, YL-90148 and YL-13027. In November 2022, its self-developed Linperlisib tablets, marketed as Intarex®, received new drug marketing approval from the National Medical Products Administration.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in